Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Folfox Protocol Clear all
Active, not recruiting Phase 2 Interventional

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

NCT06106308
View directory record Official record
Conditions
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 1 Interventional

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

NCT00501410
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-FU, Cetuximab, Dasatinib, Leucovorin, Oxaliplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 4, 2026, 12:59 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

NCT06447662
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Not listed Phase 3 Interventional

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

NCT00008281
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
121
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 4, 2026, 12:59 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis

NCT00352755
View directory record Official record
Conditions
Peritoneal Neoplasms
Interventions
Surgical debulking with peritonectomy, Intraperitoneal 5FU, FOLFOX
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

NCT00116506
View directory record Official record
Conditions
Colorectal Cancer, Neoplasm Metastasis
Interventions
erlotinib, FOLFOX, bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

NCT01047293
View directory record Official record
Conditions
Colorectal Cancer
Interventions
RAD001, FOLFOX, Bevacizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Not applicable Interventional Results available

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT00724503
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
Interventions
SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
Device · Drug
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • North Miami Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 4, 2026, 12:59 PM EDT
Active, not recruiting Phase 3 Interventional

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

NCT04919226
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00381706
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, ECF, IC, FOLFOX
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
227
States / cities
Norwalk, Connecticut • Lewes, Delaware • Newark, Delaware + 158 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 4, 2026, 12:59 PM EDT
Recruiting Phase 2 Interventional

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

NCT05024097
View directory record Official record
Conditions
Rectal Cancer
Interventions
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Terminated Phase 2 Interventional Results available

Neo-Adjuvant FOLFOX for Rectal Carcinoma

NCT00832299
View directory record Official record
Conditions
Rectal Neoplasms
Interventions
FOLFOX, total mesorectal excision (TME)
Drug · Procedure
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Sep 4, 2026, 12:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

NCT04021108
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Nivolumab 240 MG
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
Tampa, Florida • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Recruiting Phase 1 Interventional

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

NCT04808323
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Initial Dose of Radiation before Dose Escalation, Cohort A: Dose Escalation Radiation, Cohort B: Dose Escalation Radiation, Cohort C: Dose Escalation Radiation, FOLFOX
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Active, not recruiting Phase 2 Interventional

Organ Preservation in Early Rectal Cancer Patients

NCT03548961
View directory record Official record
Conditions
Rectal Cancer
Interventions
FOLFOX regimen
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT00025142
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX regimen, fluorouracil, gefitinib, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

NCT00890305
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
CT-011, FOLFOX
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Huntsville, Alabama • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 4, 2026, 12:59 PM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

NCT06704724
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Recruiting Phase 2 Interventional

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

NCT07201519
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma
Interventions
Hepatic Artery Infusion Pump (HAIP), Standard Treatment, Community Treatment, Systemic Chemotherapy Standard of Care, Standard Of Care targeting driver mutations
Device · Procedure · Drug
Lead sponsor
Michael J Cavnar, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Recruiting Phase 2 Interventional

Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

NCT06078709
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Esophagogastroduodenoscopy, Fluorouracil, Hypofractionated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Positron Emission Tomography, Survey Administration, Docetaxel, Durvalumab
Procedure · Drug · Radiation + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

NCT01516216
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFOX + bevacizumab, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
18
States / cities
Boise, Idaho • Fruitland, Idaho • Meridian, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 4, 2026, 12:59 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

NCT00959647
View directory record Official record
Conditions
Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
Interventions
Vismodegib, FOLFOX, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
10
States / cities
Scottsdale, Arizona • Oakland, California • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 4, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01418222
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-FU, FOLFOX regimen, Placebo, bevacizumab [Avastin], leucovorin, onartuzumab [MetMAb]
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
23
States / cities
San Francisco, California • Denver, Colorado • Fort Myers, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 4, 2026, 12:59 PM EDT